JP2016516734A - オートファジー誘導ペプチド類似体 - Google Patents

オートファジー誘導ペプチド類似体 Download PDF

Info

Publication number
JP2016516734A
JP2016516734A JP2016504295A JP2016504295A JP2016516734A JP 2016516734 A JP2016516734 A JP 2016516734A JP 2016504295 A JP2016504295 A JP 2016504295A JP 2016504295 A JP2016504295 A JP 2016504295A JP 2016516734 A JP2016516734 A JP 2016516734A
Authority
JP
Japan
Prior art keywords
peptide
compound
autophagy
substituted
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016504295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516734A5 (enExample
Inventor
レバイン，ベス・シー
ショージ−カワタ，サナエ
グリシン，ニック・ヴィー
キンチ，リサ・エヌ
リチタージ，オリビエ
ウィルキンス，アンジェラ・ディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2016516734A publication Critical patent/JP2016516734A/ja
Publication of JP2016516734A5 publication Critical patent/JP2016516734A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016504295A 2013-03-18 2014-02-26 オートファジー誘導ペプチド類似体 Pending JP2016516734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803095P 2013-03-18 2013-03-18
US61/803,095 2013-03-18
PCT/US2014/018467 WO2014149440A1 (en) 2013-03-18 2014-02-26 Autophagy-inducing peptide analogs

Publications (2)

Publication Number Publication Date
JP2016516734A true JP2016516734A (ja) 2016-06-09
JP2016516734A5 JP2016516734A5 (enExample) 2017-03-30

Family

ID=51267254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504295A Pending JP2016516734A (ja) 2013-03-18 2014-02-26 オートファジー誘導ペプチド類似体

Country Status (6)

Country Link
US (2) US8802633B1 (enExample)
EP (1) EP2976353B1 (enExample)
JP (1) JP2016516734A (enExample)
AU (1) AU2014238163B2 (enExample)
CA (1) CA2888759C (enExample)
WO (1) WO2014149440A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531246A (ja) * 2018-07-11 2021-11-18 イミュニティ ファルマ リミテッドImmunity Pharma Ltd. ペプチド化合物およびその治療的用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055370A1 (en) 2015-09-28 2017-04-06 Fondazione Telethon Treatment of bone growth disorders
US10993983B2 (en) 2016-03-18 2021-05-04 Trustees Of Tufts College Cyclic peptide epitopes and small-molecule mimics for inducing autophagy
US20190183908A1 (en) 2016-05-13 2019-06-20 Case Western Reserve University Autophagy activators for treating or preventing skin injury
US10618939B2 (en) 2016-06-29 2020-04-14 The Hong Kong Polytechnic University Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation
US20180002381A1 (en) * 2016-06-29 2018-01-04 The Hong Kong Polytechnic University Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation
US20230321188A1 (en) * 2020-08-19 2023-10-12 Translational Health Science And Technology Institute Autophagy inducing peptides
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
CN117223676B (zh) * 2023-09-25 2024-08-20 武汉大学 面中部发育畸形动物选育方法、辅助选育试剂和预防药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088421A2 (en) * 2010-01-15 2011-07-21 California Institute Of Technology Discovery and applications of the proteolytic function of n-terminal acetylation of cellular proteins
WO2013119377A1 (en) * 2012-02-11 2013-08-15 Board Of Regents, The University Of Texas System Autophagy-inducing peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881429B1 (fr) * 2005-02-01 2007-04-06 Servier Lab Motif de la proteine beclin interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
US20130202646A1 (en) * 2010-02-25 2013-08-08 San Diego State University (Sdsu) Foundation Compositions and methods for modulating autophagy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088421A2 (en) * 2010-01-15 2011-07-21 California Institute Of Technology Discovery and applications of the proteolytic function of n-terminal acetylation of cellular proteins
WO2013119377A1 (en) * 2012-02-11 2013-08-15 Board Of Regents, The University Of Texas System Autophagy-inducing peptide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUTOPHAGY, vol. 1, no. 1, JPN7014002200, 2005, pages 46 - 52, ISSN: 0003876136 *
S H JOO, BIOMOL THER., 2012, 20(1), PP19-26, JPN6018000191, ISSN: 0003876137 *
S PATTINGRE, ET AL., CELL, 2005, 122, PP927-939, JPN6018000194, ISSN: 0003715732 *
S S KAWATA, ET AL., NATURE, FEB.2013, 494, PP201-206, JPN6018000190, ISSN: 0003876135 *
T A AL-HILAL, ET AL., ADVANCED DRUG DELIVERY REVIEWS, 2013(AVAILABLE ONLINE 7 DEC 2012), 65, PP845-8, JPN6018000192, ISSN: 0003876138 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531246A (ja) * 2018-07-11 2021-11-18 イミュニティ ファルマ リミテッドImmunity Pharma Ltd. ペプチド化合物およびその治療的用途
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
JP2024026217A (ja) * 2018-07-11 2024-02-28 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
JP7682248B2 (ja) 2018-07-11 2025-05-23 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途

Also Published As

Publication number Publication date
US8802633B1 (en) 2014-08-12
AU2014238163B2 (en) 2015-11-26
CA2888759A1 (en) 2014-09-25
EP2976353A1 (en) 2016-01-27
US20150359840A1 (en) 2015-12-17
CA2888759C (en) 2016-11-29
WO2014149440A1 (en) 2014-09-25
AU2014238163A1 (en) 2015-09-24
EP2976353B1 (en) 2018-12-26
EP2976353A4 (en) 2016-02-10
US10300106B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
US8802633B1 (en) Autophagy-inducing peptide analogs
DK2320927T3 (en) Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
JP5715305B2 (ja) オートファジー誘導性ペプチド
BRPI0707920A2 (pt) peptìdeo monomérico, peptìdeo multimérico o compreendendo, seu uso, peptìdeo dimérico, fusão e composição farmacêutica compreendendo o mesmo, bem como métodos de detecção de fcrn in vitro, sinterização de um dìmero de peptìdeo e para purificação de fcrn
CA2979999A1 (en) Selective mcl-1 binding peptides
CA3203983A1 (en) Atf5 peptide variants and uses thereof
JP2016516734A5 (enExample)
ES2275542T3 (es) Compuestos sinteticos que portan dos epitopes para inmunodosificaciones.
US12552846B2 (en) Modified BCL9 mimetic peptides
CN101421297A (zh) 阻断lgG对FcRn的结合的肽
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
Bingham et al. Synthesis of an iberiotoxin derivative by chemical ligation: A method for improved yields of cysteine-rich scorpion toxin peptides
Eiríksdottir et al. Cellular uptake of cell-penetrating peptides
US12595289B2 (en) Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2
CA2509423A1 (en) Peptides and their use for the treatment of hiv infections
CA2319207A1 (en) Peptides with .beta.1 integrin subunit dependent cell adhesion modulating activity
Jha Development of a New Cell Penetrating Peptide: Design, Synthesis and Applications
WO2026085280A1 (en) Cell-penetrating peptides with enhanced solubility
Class et al. Patent application title: ATF5 Peptide Variants and Uses Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20181221

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190204

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190205

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190301

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190305

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190820

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20191119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200213

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200616

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20200721

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200721